Sellas Life Sciences Group Inc (NASDAQ:SLS)
| 1.71 Delayed Data As of 3:59pm ET |  +0.02 / +1.18%Today’s Change | 1.17 Today|||52-Week Range 5.58 | -27.54% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | -39.0M | -11.1M | -23.8M | -27.7M | |
| Depreciation | 355.0K | 142.0K | 0.00 | -- | ||
| Total Other Cash Flow | -8.1M | -31.0M | 6.7M | 8.6M | ||
| Funds From Operations | -46.3M | -41.7M | -17.1M | -20.4M | ||
| Funds From/For Other Operating Expenses | 1.8M | 3.2M | -6.1M | 10.0M | ||
| Net Cash Flow - Operating Activities | -48.2M | -44.9M | -11.0M | -30.4M | ||
| Investing | Capital Expenditures | -153.0K | -6.0K | 0.00 | -- | |
| Fixed Asset Disposal | -- | -- | 1.8M | 0.00 | ||
| Other Investing - Uses | 0.00 | -1.1M | 0.00 | 0.00 | ||
| Other Investing - Sources | 10.7M | 0.00 | 0.00 | 0.00 | ||
| Net Cash Flow Investing | 10.6M | -1.1M | 1.8M | 0.00 | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 0.00 | 23.4M | 0.00 | 0.00 | ||
| Long Term Debt Reduction | -3.9M | -23.2M | -473.0K | -7.6M | ||
| Net Proceeds Stock Sale | 47.8M | 34.1M | 6.0M | 31.2M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | 0.00 | 0.00 | 0.00 | -487.0K | ||
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | -487.0K | ||
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Cash Flow - Financing | 43.8M | 34.3M | 5.5M | 23.1M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -- | -- | -- | -- | -- |
| Net Change In Cash | 6.3M | -11.6M | -3.6M | -7.3M | ||
